Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.34 |
| ▸ | CDC25B | P30305 | 7/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.33 |
| ▸ | GJB2 | P29033 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29113115 | 1.00 | PDE2A (0.39) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL31063739 | 0.92 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL12393373 | 0.92 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL27086454 | 0.92 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL12243141 | 0.92 | PDE2A (0.37) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL13667906 | 0.90 | HSPA5 (0.38) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL31725287 | 0.89 | PDE2A (0.38) | PDE2AHSPA5HTR1ATNK2 | |
| SCHEMBL18666866 | 0.88 | PDE2A (0.38) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL24058130 | 0.88 | PDE2A (0.39) | PDE2AHSPA5PTPN1CDC25BHTR1A | |
| SCHEMBL18636427 | 0.88 | PDE2A (0.39) | PDE2AHSPA5PTPN1CDC25BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3785717-B1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210061806-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
| CN-110724174-A | Pyrrolotriazine compound, composition and application thereof | 嘉兴金派特生物科技有限公司 | 2020-01-24 | — | — | CN | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190055251-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017049060-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061806-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | PDE2A 1863/4885HSPA5 4656/4885PTPN1 1838/4885 |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, NSUN2 | PDE2A 1006/4885HSPA5 4597/4885PTPN1 1695/4885 |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | PNP, RPIA, HPRT1 | PDE2A 1863/4885HSPA5 4656/4885PTPN1 1838/4885 |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | PDE2A 3746/4885HSPA5 3890/4885PTPN1 2220/4885 |
| US-20190055251-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | PDE2A 1863/4885HSPA5 4656/4885PTPN1 1838/4885 |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | PDE2A 3746/4885HSPA5 3890/4885PTPN1 2220/4885 |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | PDE2A 3746/4885HSPA5 3890/4885PTPN1 2220/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | PDE2A 4326/4885HSPA5 1453/4885PTPN1 4253/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | PDE2A 3746/4885HSPA5 3890/4885PTPN1 2220/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | PDE2A 1863/4885HSPA5 4656/4885PTPN1 1838/4885 |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | PDE2A 3746/4885HSPA5 3890/4885PTPN1 2220/4885 |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | PDE2A 3746/4885HSPA5 3890/4885PTPN1 2220/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | PDE2A 3746/4885HSPA5 3890/4885PTPN1 2220/4885 |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | PDE2A 2331/4885HSPA5 2324/4885PTPN1 4868/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | PDE2A 3717/4885HSPA5 3887/4885PTPN1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.